Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s12026-021-09244-x http://scihub22266oqcxt.onion/10.1007/s12026-021-09244-x 34739696!8570229!34739696     free     free     free       Immunol+Res 2022 ; 70 (1): 129-133 Nephropedia Template TP {{tp|p=34739696|t=2022. A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?|pdf=|usr=}}{{34739696}} gab.com Text A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy JO: Immunol Res http://www.kidney.de/pget.php?&tw=1&pmid=34739696 #FOAvip Azithromycin is a macrolide antibiotic. Recent evidence has demonstrated in vitro activity against a wide variety of respiratory tract viruses, including SARS-CoV-2 responsible for the current global pandemic COVID-19. A mechanism of action acting on different phases of the viral cycle is assumed. In addition to its in vitro antiviral properties, some evidence also suggests immunomodulatory and antifibrotic activity. These properties of azithromycin could be useful in the treatment of viral respiratory tract infections such as COVID-19. However, clinical data on the antiviral efficacy of azithromycin in the treatment of respiratory tract infections are inconsistent, both when used as monotherapy and in polypharmacological combination. In addition, cases of azithromycin-induced QT long and malignant arrhythmias are reported. In this short review, we attempt to determine the role of azithromycin in the treatment of viral respiratory tract infections such as COVID-19, therapeutic efficacy, or inefficacy? Twit Text FOAVip A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy ????Immunol Res http://www.kidney.de/pget.php?&tw=1&pmid=34739696 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34739696 #FOAvip English Wikipedia <ref>{{Cite pmid|34739696}}</ref> A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy? #MMPMID34739696 Vitiello A; Ferrara F Immunol Res 2022[Feb]; 70 (1): 129-133 PMID34739696show ga Azithromycin is a macrolide antibiotic. Recent evidence has demonstrated in vitro activity against a wide variety of respiratory tract viruses, including SARS-CoV-2 responsible for the current global pandemic COVID-19. A mechanism of action acting on different phases of the viral cycle is assumed. In addition to its in vitro antiviral properties, some evidence also suggests immunomodulatory and antifibrotic activity. These properties of azithromycin could be useful in the treatment of viral respiratory tract infections such as COVID-19. However, clinical data on the antiviral efficacy of azithromycin in the treatment of respiratory tract infections are inconsistent, both when used as monotherapy and in polypharmacological combination. In addition, cases of azithromycin-induced QT long and malignant arrhythmias are reported. In this short review, we attempt to determine the role of azithromycin in the treatment of viral respiratory tract infections such as COVID-19, therapeutic efficacy, or inefficacy? |*COVID-19 Drug Treatment[MESH] |Antiviral Agents/*administration & dosage/adverse effects[MESH] |Azithromycin/adverse effects/*therapeutic use[MESH] |COVID-19/metabolism[MESH] |Humans[MESH] |Long QT Syndrome/chemically induced/metabolism[MESH]A short focus, azithromycin in the treatment of respiratory viral infe(epmc).pdf DeepDyve Pubget Overpricing